AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 30475213 — intervention group
Group type: EXPERIMENTAL
Intervention: Unmatched Count Technique (UCT)
Number of subjects: 708
Study 30475213 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomized Response Technique (RRT)
Number of subjects: 708
Study 27858075 — intervention group
Group type: EXPERIMENTAL
Intervention: Nd:YAG laser combined with total glucosides of paeony (TGP)
Number of subjects: 60
Study 27858075 — intervention group
Group type: COMPARATOR
Intervention: Total glucosides of paeony (TGP)
Number of subjects: 60
Study 27858075 — intervention group
Group type: EXPERIMENTAL
Intervention: Nd:YAG laser combined with TGP
Number of subjects: 60
Study 24234676 — intervention group
Group type: EXPERIMENTAL
Intervention: Hands-on participation group (manual guidance and tactile prompting)
Number of subjects: 34
Study 24234676 — intervention group
Group type: COMPARATOR
Intervention: Observation group (hearing words and watching task)
Number of subjects: 34
Study 22430681 — intervention group
Group type: EXPERIMENTAL
Intervention: Contrast-enhanced ultrasonography (CEUS)
Number of subjects: 88
Study 22430681 — intervention group
Group type: COMPARATOR
Intervention: Triple-phase computed tomography angiography (CTA)
Number of subjects: 88
Study 20926264 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertindole
Number of subjects: 9809
Study 20926264 — intervention group
Group type: COMPARATOR
Intervention: Risperidone
Number of subjects: 9809
Study 20926264 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 9809
Study 18674978 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized pressure ulcer education and monthly structured telephone follow-up (n=20)
Number of subjects: 41
Study 18674978 — intervention group
Group type: COMPARATOR
Intervention: Monthly mail or telephone follow-up without educational content (n=11)
Number of subjects: 41
Study 18674978 — intervention group
Group type: COMPARATOR
Intervention: Quarterly mail or telephone follow-up without educational content (n=10)
Number of subjects: 41
Study 16197666 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin 40 mg/day
Number of subjects: 18
Study 16197666 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 11979058 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbamazepine (CBZ)
Number of subjects: 20
Study 11979058 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 10403866 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.2 ml 0.5% bupivacaine (6 mg)
Number of subjects: 60
Study 10403866 — intervention group
Group type: COMPARATOR
Intervention: 3.4 ml 0.18% hypobaric bupivacaine (6.1 mg)
Number of subjects: 60
Study 8534058 — intervention group
Group type: EXPERIMENTAL
Intervention: Isopropyl alcohol prep/iodophor‐impregnated adhesive drape method
Number of subjects: 0
Study 8534058 — intervention group
Group type: COMPARATOR
Intervention: Iodophor scrub and paint prep/plain adhesive drape method
Number of subjects: 0
Study 2333740 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up formula with 1.5 g protein/dl (2.0 g/kg/d)
Number of subjects: 0
Study 2333740 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up formula with 2.2 g protein/dl (3.0 g/kg/d)
Number of subjects: 0
Study 2333740 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up formula with 2.9 g protein/dl (3.7 g/kg/d)
Number of subjects: 0
Study 2333740 — intervention group
Group type: COMPARATOR
Intervention: Formula only (15 g/dl)
Number of subjects: 0
Study 6999291 — intervention group
Group type: EXPERIMENTAL
Intervention: Probucol (1000 mg/day)
Number of subjects: 19
Study 6999291 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 31327051 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-to-high intensity exercise with person-centered guidance
Number of subjects: 74
Study 31327051 — intervention group
Group type: COMPARATOR
Intervention: Home-based exercise of light intensity (control)
Number of subjects: 74
Study 29658258 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional Chinese medicine (TCM) fumigation plus oral Levofloxacin
Number of subjects: 72
Study 29658258 — intervention group
Group type: COMPARATOR
Intervention: Oral Levofloxacin only
Number of subjects: 72
Study 26480551 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical stimulation at Renying (ST 9) combined with stellate ganglion block (SGB)
Number of subjects: 60
Study 26480551 — intervention group
Group type: COMPARATOR
Intervention: Simple SGB
Number of subjects: 60
Study 23642941 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus (10 mg)
Number of subjects: 118
Study 23642941 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 118
Study 21288210 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracetamol + Pregabalin + Dexamethasone
Number of subjects: 131
Study 21288210 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracetamol + Pregabalin
Number of subjects: 131
Study 21288210 — intervention group
Group type: COMPARATOR
Intervention: Paracetamol + Placebo
Number of subjects: 131
Study 19834266 — intervention group
Group type: EXPERIMENTAL
Intervention: Follicle phase
Number of subjects: 12
Study 19834266 — intervention group
Group type: EXPERIMENTAL
Intervention: Luteal phase
Number of subjects: 12
Study 19834266 — intervention group
Group type: EXPERIMENTAL
Intervention: Menstruation phase
Number of subjects: 12
Study 16456410 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus casei shirota (LCS)
Number of subjects: 28
Study 14976782 — intervention group
Group type: EXPERIMENTAL
Intervention: rapacuronium 1000 micrograms.Kg‐1 (bolus)
Number of subjects: 120
Study 14976782 — intervention group
Group type: EXPERIMENTAL
Intervention: rapacuronium 100 micrograms.Kg‐1 (priming)
Number of subjects: 120
Study 14976782 — intervention group
Group type: EXPERIMENTAL
Intervention: rocuronium 400 micrograms.Kg‐1 (bolus)
Number of subjects: 120
Study 14976782 — intervention group
Group type: EXPERIMENTAL
Intervention: rocuronium 60 micrograms.Kg‐1 (priming)
Number of subjects: 120
Study 14976782 — intervention group
Group type: EXPERIMENTAL
Intervention: mivacurium 100 micrograms.Kg‐1 (bolus)
Number of subjects: 120
Study 14976782 — intervention group
Group type: EXPERIMENTAL
Intervention: mivacurium 10 micrograms.Kg‐1 (priming)
Number of subjects: 120
Study 14976782 — intervention group
Group type: EXPERIMENTAL
Intervention: mivacurium (priming)
Number of subjects: 120
Study 11156123 — intervention group
Group type: EXPERIMENTAL
Intervention: SMA group (surface modifying additives circuit)
Number of subjects: 100
Study 11156123 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 100
Study 9201061 — intervention group
Group type: EXPERIMENTAL
Intervention: PEEP at 5 cm H2O
Number of subjects: 18
Study 9201061 — intervention group
Group type: EXPERIMENTAL
Intervention: PEEP at 10 cm H2O
Number of subjects: 18
Study 9201061 — intervention group
Group type: EXPERIMENTAL
Intervention: PEEP at 15 cm H2O
Number of subjects: 18
Study 9201061 — intervention group
Group type: EXPERIMENTAL
Intervention: PEEP levels (5, 10, 15 cm H2O)
Number of subjects: 18
Study 1436902 — intervention group
Group type: EXPERIMENTAL
Intervention: Scintigraphy with 99Tcm-HMPAO-labelled platelets
Number of subjects: 33
Study 3898440 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftriaxone (1 gram preoperative dose)
Number of subjects: 225
Study 3898440 — intervention group
Group type: COMPARATOR
Intervention: Cefazolin (three 1 gram parenteral doses over a 16 hour period)
Number of subjects: 225
Study 31385425 — intervention group
Group type: EXPERIMENTAL
Intervention: IDegLira
Number of subjects: 506
Study 31385425 — intervention group
Group type: COMPARATOR
Intervention: Basal-bolus therapy
Number of subjects: 506
Study 29852180 — intervention group
Group type: EXPERIMENTAL
Intervention: Decision aid exposure
Number of subjects: 1336
Study 29852180 — intervention group
Group type: EXPERIMENTAL
Intervention: Decision aid from the United States Preventive Services Task Force
Number of subjects: 1336
Study 27670865 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based intervention (MBI)
Number of subjects: 18
Study 27670865 — intervention group
Group type: COMPARATOR
Intervention: Standard intervention
Number of subjects: 18
Study 24641678 — intervention group
Group type: EXPERIMENTAL
Intervention: levodopa 0.76 mg/kg with 25% carbidopa
Number of subjects: 45
Study 24641678 — intervention group
Group type: EXPERIMENTAL
Intervention: levodopa 0.51 mg/kg with 25% carbidopa
Number of subjects: 45
Study 24641678 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 45
Study 22729015 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture treatment
Number of subjects: 40
Study 22729015 — intervention group
Group type: COMPARATOR
Intervention: Sham acupuncture
Number of subjects: 40
Study 20425703 — intervention group
Group type: EXPERIMENTAL
Intervention: Early atropine protocol (Group 2)
Number of subjects: 100
Study 20425703 — intervention group
Group type: COMPARATOR
Intervention: Conventional protocol (Group 1)
Number of subjects: 100
Study 18823469 — intervention group
Group type: COMPARATOR
Intervention: 30 mg ketorolac i.v. after induction of anaesthesia
Number of subjects: 133
Study 18823469 — intervention group
Group type: EXPERIMENTAL
Intervention: 120 mg etoricoxib orally as premedication
Number of subjects: 133
Study 15932662 — intervention group
Group type: EXPERIMENTAL
Intervention: Successful PCI group
Number of subjects: 64
Study 15932662 — intervention group
Group type: COMPARATOR
Intervention: Control group (not receiving PCI or IRA not re‐opened)
Number of subjects: 64
Study 12460706 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan (50 mg/day)
Number of subjects: 11
Study 12460706 — intervention group
Group type: COMPARATOR
Intervention: Hydrochlorthiazide (12.5 mg/day)
Number of subjects: 11
Study 10783990 — intervention group
Group type: EXPERIMENTAL
Intervention: Palliative chemotherapy
Number of subjects: 0
Study 10783990 — intervention group
Group type: EXPERIMENTAL
Intervention: Current chemotherapy options
Number of subjects: 0
Study 10783990 — intervention group
Group type: EXPERIMENTAL
Intervention: New developments in chemotherapy
Number of subjects: 0
Study 8842510 — intervention group
Group type: EXPERIMENTAL
Intervention: Active treatment (transdermal nicotine patches)
Number of subjects: 50
Study 8842510 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 1345755 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy with zidovudine and dideoxycytidine (ddC)
Number of subjects: 56
Study 1345755 — intervention group
Group type: EXPERIMENTAL
Intervention: Regimens containing 600 mg of zidovudine daily (regimens 2 and 5)
Number of subjects: 56
Study 1345755 — intervention group
Group type: COMPARATOR
Intervention: Lowest zidovudine dose alone (regimen 6)
Number of subjects: 56
Study 1345755 — intervention group
Group type: EXPERIMENTAL
Intervention: Addition of ddC to regimen 6 (regimen 3)
Number of subjects: 56
Study 1345755 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy with zidovudine and ddC at the doses tested
Number of subjects: 56
Study 1345755 — intervention group
Group type: COMPARATOR
Intervention: Daily oral dose of 150 mg of zidovudine
Number of subjects: 56
Study 6735963 — intervention group
Group type: EXPERIMENTAL
Intervention: Oltipraz administered under fasting conditions (25 mg/kg)
Number of subjects: 7
Study 6735963 — intervention group
Group type: EXPERIMENTAL
Intervention: Oltipraz administered with a low fat meal (less than 5% fat)
Number of subjects: 7
Study 6735963 — intervention group
Group type: EXPERIMENTAL
Intervention: Oltipraz administered with a high fat meal (24% fat)
Number of subjects: 7
Study 31115592 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoledronic acid (5 mg intravenous infusion) + calcium + calcitriol
Number of subjects: 40
Study 31115592 — intervention group
Group type: COMPARATOR
Intervention: Calcium + calcitriol
Number of subjects: 40
Study 28011183 — intervention group
Group type: EXPERIMENTAL
Intervention: Mono-cortical plate fixation
Number of subjects: 76
Study 28011183 — intervention group
Group type: EXPERIMENTAL
Intervention: Hybrid fixation
Number of subjects: 76
Study 28011183 — intervention group
Group type: COMPARATOR
Intervention: Bi-cortical plate fixation
Number of subjects: 76
Study 25043261 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical stimulation (ES) at 5 and 50 Hz, with pulse durations of 20, 100, 400, 1000, and 3000 μs.
Number of subjects: 80
Study 23657766 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole body vibration training (WBV)
Number of subjects: 40
Study 23657766 — intervention group
Group type: COMPARATOR
Intervention: Usual-care control (CON)
Number of subjects: 40
Study 21644105 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine 0.2 mg
Number of subjects: 60
Study 21644105 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl 25 µg
Number of subjects: 60
Study 21644105 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl 12.5 µg plus Morphine 0.1 mg
Number of subjects: 60
Study 21644105 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 60
Study 18259794 — intervention group
Group type: EXPERIMENTAL
Intervention: New ultrasonic scissors
Number of subjects: 100
Study 18259794 — intervention group
Group type: COMPARATOR
Intervention: Resterilized ultrasonic scissors
Number of subjects: 100
Study 16491208 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed combination of amlodipine and losartan
Number of subjects: 198
Study 16491208 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine alone
Number of subjects: 198
Study 16491208 — intervention group
Group type: COMPARATOR
Intervention: Losartan alone
Number of subjects: 198
Study 12794792 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous doxycycline
Number of subjects: 30
Study 11551003 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-year hospital-based secondary prevention programme (SPP)
Number of subjects: 241
Study 11551003 — intervention group
Group type: COMPARATOR
Intervention: Conventional care (CC)
Number of subjects: 241
Study 9242857 — intervention group
Group type: EXPERIMENTAL
Intervention: Original instructions
Number of subjects: 60
Study 9242857 — intervention group
Group type: EXPERIMENTAL
Intervention: Revised instructions
Number of subjects: 60
Study 9242857 — intervention group
Group type: EXPERIMENTAL
Intervention: Second revised instructions
Number of subjects: 60
Study 8486017 — intervention group
Group type: EXPERIMENTAL
Intervention: Unsupported arm exercise (UAEx)
Number of subjects: 40
Study 8486017 — intervention group
Group type: COMPARATOR
Intervention: Supported arm exercise (SAEx)
Number of subjects: 40
Study 3129362 — intervention group
Group type: EXPERIMENTAL
Intervention: rIFN-gamma (0.01 mg)
Number of subjects: 0
Study 3129362 — intervention group
Group type: EXPERIMENTAL
Intervention: rIFN-gamma (0.1 mg)
Number of subjects: 0
Study 3129362 — intervention group
Group type: EXPERIMENTAL
Intervention: rIFN-gamma (0.5 mg)
Number of subjects: 0
Study 3129362 — intervention group
Group type: EXPERIMENTAL
Intervention: rIFN-gamma (all doses)
Number of subjects: 0
Study 3129362 — intervention group
Group type: EXPERIMENTAL
Intervention: rIFN-gamma (highest dose level)
Number of subjects: 0
Study 2806493 — intervention group
Group type: EXPERIMENTAL
Intervention: terbutaline
Number of subjects: 9
Study 2806493 — intervention group
Group type: EXPERIMENTAL
Intervention: tobacco exposure
Number of subjects: 9
Study 2806493 — intervention group
Group type: EXPERIMENTAL
Intervention: combination of smoking and terbutaline
Number of subjects: 9
Study 2806493 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 9
Study 31523780 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean diet (MedDiet) adherence improvement
Number of subjects: 5777
Study 29449791 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (CAF) 200 mg
Number of subjects: 20
Study 29449791 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLA) 200 mg dextrose
Number of subjects: 20
Study 29449791 — intervention group
Group type: COMPARATOR
Intervention: Control (CON) no supplementation
Number of subjects: 20
Study 27723543 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose curcumin extract (250mg b.i.d.)
Number of subjects: 123
Study 27723543 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose curcumin extract (500mg b.i.d.)
Number of subjects: 123
Study 27723543 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined low-dose curcumin extract plus saffron (15mg b.i.d.)
Number of subjects: 123
Study 27723543 — intervention group
Group type: EXPERIMENTAL
Intervention: Active drug treatments (combined)
Number of subjects: 123
Study 27723543 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 123
Study 25262675 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythritol air-polishing powder (EPAP)
Number of subjects: 40
Study 25262675 — intervention group
Group type: COMPARATOR
Intervention: Scaling and root planing (SRP)
Number of subjects: 40
Study 23199378 — intervention group
Group type: EXPERIMENTAL
Intervention: rhBMP-2 treatment
Number of subjects: 508
Study 23199378 — intervention group
Group type: COMPARATOR
Intervention: Control group (autograft or lumbar disc treatment)
Number of subjects: 508
Study 23199378 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical approach (retroperitoneal)
Number of subjects: 508
Study 23199378 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical approach (transperitoneal)
Number of subjects: 508
Study 21499725 — intervention group
Group type: EXPERIMENTAL
Intervention: Lysine hyaluronate (Lys-HA)
Number of subjects: 50
Study 21499725 — intervention group
Group type: COMPARATOR
Intervention: Sodium hyaluronate (SH)
Number of subjects: 50
Study 18450417 — intervention group
Group type: EXPERIMENTAL
Intervention: Frontal Systems Behavioral Scale (FrSBe) for F-ABI patients
Number of subjects: 139
Study 18450417 — intervention group
Group type: EXPERIMENTAL
Intervention: Frontal Systems Behavioral Scale (FrSBe) for substance abusers
Number of subjects: 139
Study 18450417 — intervention group
Group type: EXPERIMENTAL
Intervention: Frontal Systems Behavioral Scale (FrSBe) total score for F-ABI patients
Number of subjects: 139
Study 18450417 — intervention group
Group type: EXPERIMENTAL
Intervention: Frontal Systems Behavioral Scale (FrSBe) total score for substance abusers
Number of subjects: 139
Study 18450417 — intervention group
Group type: COMPARATOR
Intervention: Frontal Systems Behavioral Scale (FrSBe) total score for controls
Number of subjects: 139
Study 16506027 — intervention group
Group type: COMPARATOR
Intervention: autologous iliac graft (n=6)
Number of subjects: 17
Study 16506027 — intervention group
Group type: EXPERIMENTAL
Intervention: autologous iliac graft + osteogenic protein-1 (OP-1; n=6)
Number of subjects: 17
Study 16506027 — intervention group
Group type: EXPERIMENTAL
Intervention: allogenic iliac graft + OP-1 (n=5)
Number of subjects: 17
Study 15531489 — intervention group
Group type: EXPERIMENTAL
Intervention: r-metHuLeptin (0.05 mg/kg sc daily)
Number of subjects: 17
Study 15531489 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 11579010 — intervention group
Group type: EXPERIMENTAL
Intervention: Tandospirone (30 mg/day)
Number of subjects: 26
Study 11579010 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 9217971 — intervention group
Group type: EXPERIMENTAL
Intervention: Fas ligand (FasL) expression in glioblastoma cell lines and primary astrocytic brain tumors
Number of subjects: 24
Study 9217971 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunohistochemical assessment of FasL
Number of subjects: 24
Study 9217971 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction of Fas expression
Number of subjects: 24
Study 7968119 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxycillin (500 mg three times daily for 7 days)
Number of subjects: 210
Study 7968119 — intervention group
Group type: COMPARATOR
Intervention: Erythromycin (500 mg four times daily for 7 days)
Number of subjects: 210
Study 3475663 — intervention group
Group type: EXPERIMENTAL
Intervention: Local anesthetic blocking of the auriculotemporal nerve
Number of subjects: 208
Study 3475663 — intervention group
Group type: COMPARATOR
Intervention: Placebo injections of saline solution
Number of subjects: 208
Study 29224730 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction of labor with an unfavorable cervix (Bishop score ≤6 and dilation ≤2 cm)
Number of subjects: 8466
Study 29224730 — intervention group
Group type: EXPERIMENTAL
Intervention: Nomogram and Web-based calculator for predicting cesarean delivery
Number of subjects: 8466
Study 26163860 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Cognitive Therapy (MBCT)
Number of subjects: 21
Study 24962851 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral nitric oxide supplement (lozenge)
Number of subjects: 30
Study 24962851 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 22343481 — intervention group
Group type: EXPERIMENTAL
Intervention: Kripalu-based yoga program (2 to 3 times a week for 10 weeks)
Number of subjects: 51
Study 22343481 — intervention group
Group type: COMPARATOR
Intervention: PE-as-usual (control group)
Number of subjects: 51
Study 20524068 — intervention group
Group type: EXPERIMENTAL
Intervention: MedCoat coated placebo tablets
Number of subjects: 41
Study 20524068 — intervention group
Group type: EXPERIMENTAL
Intervention: MedCoat coated divided non-flavoured placebo tablets
Number of subjects: 41
Study 20524068 — intervention group
Group type: EXPERIMENTAL
Intervention: MedCoat coated bitter flavoured placebo tablets
Number of subjects: 41
Study 20524068 — intervention group
Group type: EXPERIMENTAL
Intervention: MedCoat
Number of subjects: 41
Study 18955426 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured educational programme of daily incremental physical activity at home (walking and skeletal muscle resistance training, with booklets and written instructions)
Number of subjects: 52
Study 18955426 — intervention group
Group type: COMPARATOR
Intervention: General advice regarding exercise and long-term fitness (control group)
Number of subjects: 52
Study 16164766 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief eclectic psychotherapy for 4 months (n=9)
Number of subjects: 18
Study 16164766 — intervention group
Group type: COMPARATOR
Intervention: Waiting-list group (n=9)
Number of subjects: 18
Study 16164766 — intervention group
Group type: EXPERIMENTAL
Intervention: PTSD patients (n=18)
Number of subjects: 18
Study 16164766 — intervention group
Group type: COMPARATOR
Intervention: Traumatized control subjects (n=14)
Number of subjects: 18